Mount Sinai Institute of Technology

At Mount Sinai Institute of Technology (MSIT), our goal is to radically transform biomedicine through the discovery, design, development, and delivery of entrepreneurially-driven, technology-based solutions to critical unmet medical needs. 

Collaboration — across disciplines and organizations — drives our work forward. We bring together the resources and expertise of a top academic medical center with the creativity, flexibility, and commercialization opportunities of an entrepreneurially focused organization. Join us as we build an institute poised to catalyze biomedical innovation.

In 2013 the Icahn School of Medicine at Mount Sinai established Mount Sinai Institute of Technology (MSIT) with $5 million in funding provided by the New York City Economic Development Corporation. Building on the school’s commitment to the discovery and development of novel biomedical technologies benefiting patients, we seek to focus our research efforts on the critical open issues of biomedicine today.

DTE Makers Studio design team demonstrating their working prototype of a high-throughput cell compression device.

DTE Makers Studio design team demonstrating their working prototype of a high-throughput cell compression device.

This approach is inherently different from most traditionally-funded biomedical research:

  • There is no precedent for some of these problems. In many cases you cannot build off of something else to address them. These are typically not incremental problems.
  • Gaining traction against these problems often requires developing new algorithms, new technology, and dedicated infrastructure. These are typically technically and technologically demanding problems.
  • The metrics of success diverge from the current NIH-based granting model. They will require faculty and external collaborators who are at the interface of several fields. They will require interdisciplinary teams. These are, without exception, team-based problems on a different scope and timescale from standard R01 grants.

Solving problems of this kind requires an institute organized to think and act differently.

MSIT is neither a pure discovery organization, nor a pure application organization. The Institute sits at the intersection of these two areas and seeks to drive technology development by using the tension created at this intersection to drive innovation.


  1. Solve critical open biomedical problems by increasing innovative technology development through the convergence of biology, design, engineering, and entrepreneurship.
  2. Use problem-based learning to provide education and training relevant to technology development for students and faculty.
  3. Partner with industry, academia, foundations, and government for problem solving and education.
  4. Drive innovation, entrepreneurship, and technology development policy and research in order to shape the economic, legal, scientific, and public policy issues affecting biomedical innovation worldwide through the Center for Technology, Innovation, and Entrepreneurship (cTIE).

Primary Technology Categories

  • Digital Health Technologies including mobile health, wireless health, Big Data, cloud computing, social networking, scientific computing, and scientific and clinical simulation
  • Biologically Integrated Technologies including tissue engineering, sensors, microprocessors, robotics, mechatronics, MEMs, and microfluidics
  • Prescription Technologies including drug repurposing, drug delivery, nanomedicine, and medical devices.